Patents by Inventor Steven J. Kridel
Steven J. Kridel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10071076Abstract: Active compounds useful for inhibiting fatty acid synthase in a subject in need thereof are described. The active compounds are, in general, a 5-mercapto-1H-Indazole-4,7-dione or an analog thereof. The compounds are useful for treating subjects afflicted with, cancer, obesity, diabetes, a viral infection, a bacterial infection, a fungal infection, or a protozoal infection.Type: GrantFiled: June 27, 2016Date of Patent: September 11, 2018Assignee: Wake Forest University Health SciencesInventors: Steven J. Kridel, W. Todd Lowther, Herman H. Odens, Jeffrey D. Schmitt
-
Publication number: 20160317496Abstract: Active compounds useful for inhibiting fatty acid synthase in a subject in need thereof are described. The active compounds are, in general, a 5-mercapto-1H-Indazole-4,7-dione or an analog thereof. The compounds are useful for treating subjects afflicted with, cancer, obesity, diabetes, a viral infection, a bacterial infection, a fungal infection, or a protozoal infection.Type: ApplicationFiled: June 27, 2016Publication date: November 3, 2016Inventors: Steven J. Kridel, W. Todd Lowther, Herman H. Odens, Jeffrey D. Schmitt
-
Publication number: 20130345270Abstract: Active compounds useful for inhibiting fatty acid synthase in a subject in need thereof are described. The active compounds are, in general, a 5-mercapto-1H-Indazole-4,7-dione or an analog thereof. The compounds are useful for treating subjects afflicted with, cancer, obesity, diabetes, a viral infection, a bacterial infection, a fungal infection, or a protozoal infection.Type: ApplicationFiled: November 7, 2011Publication date: December 26, 2013Applicant: Waake Forest University Health SciencesInventors: Steven J. Kridel, W. Todd Lowther, Herman W. Odens, Jeffrey D. Schmitt
-
Patent number: 8124794Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.Type: GrantFiled: November 17, 2009Date of Patent: February 28, 2012Assignee: Sanford-Burnham Medical Research InstituteInventors: Jeffrey W. Smith, Fumiko Axelrod, Steven J. Kridel, Daniel Romo, Vikram Purohit, Gil Ma
-
Patent number: 7935785Abstract: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety.Type: GrantFiled: October 15, 2008Date of Patent: May 3, 2011Assignee: Sanford-Burnham Medical Research InstituteInventors: Jeffrey W. Smith, Emily I. Chen, Steven J. Kridel
-
Patent number: 7799826Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis.Type: GrantFiled: April 16, 2003Date of Patent: September 21, 2010Assignee: Burnham Institute for Medical ResearchInventors: Jeffrey W. Smith, Fumiko Axelrod, Steven J. Kridel
-
Publication number: 20100173982Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.Type: ApplicationFiled: November 17, 2009Publication date: July 8, 2010Applicant: The Burnham Institute for Medical ResearchInventors: Jeffrey W. Smith, Fumiko Axelrod, Steven J. Kridel, Daniel Romo, Vikram Purohit, Gil Ma
-
Patent number: 7728153Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.Type: GrantFiled: March 16, 2006Date of Patent: June 1, 2010Assignee: The Burnham Institute for Medical ResearchInventors: Jeffrey W. Smith, Fumiko Axelrod, Steven J. Kridel, Daniel Romo, Vikram Purohit, Gil Ma
-
Publication number: 20090253896Abstract: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety.Type: ApplicationFiled: October 15, 2008Publication date: October 8, 2009Applicant: Burnham Institute for Medical ResearchInventors: Jeffrey W. Smith, Emily I. Chen, Steven J. Kridel
-
Publication number: 20090155828Abstract: Proteins specific for prostate epithelial cells, normal or neoplastic, are identified and used for diagnosis, development of antibodies, and for evaluating drugs that react with the neoplastic specific proteins. Affinity based probes are used that react specifically with the active site to provide a measure of the enzyme activity of the cells. Prostate epithelial neoplastic cells can be used in screening candidate drugs for their effect in changing the proteome profile as to the serine-threonine hydrolase enzymes, using the affinity based probes for determining the profile.Type: ApplicationFiled: September 12, 2008Publication date: June 18, 2009Applicant: The Burnham Institute for Medical ResearchInventors: Jeffrey W. Smith, Steven J. Kridel, Fumiko T. Axelrod
-
Patent number: 7439319Abstract: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety.Type: GrantFiled: September 13, 2002Date of Patent: October 21, 2008Assignee: Burnham Institute for Medical ResearchInventors: Jeffrey W. Smith, Emily I. Chen, Steven J. Kridel
-
Publication number: 20040053823Abstract: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety.Type: ApplicationFiled: September 13, 2002Publication date: March 18, 2004Inventors: Jeffrey W. Smith, Emily I. Chen, Steven J. Kridel
-
Publication number: 20040024050Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis.Type: ApplicationFiled: April 16, 2003Publication date: February 5, 2004Inventors: Jeffrey W. Smith, Fumiko Axelrod, Steven J. Kridel
-
Publication number: 20030096328Abstract: Proteins specific for prostate epithelial cells, normal or neoplastic, are identified and used for diagnosis, development of antibodies, and for evaluating drugs that react with the neoplastic specific proteins. Affinity based probes are used that react specifically with the active site to provide a measure of the enzyme activity of the cells. Prostate epithelial neoplastic cells can be used in screening candidate drugs for their effect in changing the proteome profile as to the serine-threonine hydrolase enzymes, using the affinity based probes for determining the profile.Type: ApplicationFiled: September 4, 2002Publication date: May 22, 2003Inventors: Jeffrey W. Smith, Steven J. Kridel, Fumiko T. Axelrod